Control vaccine

BIOLOGICAL6 trials

Sponsors

Butantan Institute, International Vaccine Institute, Sinovac Biotech Co., Ltd, GlaxoSmithKline, Hualan Biological Bacterin Co. Ltd.

Conditions

Acute Respiratory InfectionCOVID-19Hand, Foot and Mouth DiseaseInfluenzaRabies HumanSARS-CoV-2ShigellosisTyphoid

Phase 2

A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults

CompletedNCT05960097

GlaxoSmithKlineCOVID-19, SARS-CoV-2

Start: 2023-08-01End: 2024-08-30Updated: 2025-10-23

A study to expand safety and immunogenicity data with the second generation of the Shigella bioconjugate tetravalent (Shigella4V2) in 9-month-old Kenyan infants.

Active, not recruitingPACTR202408653853505

LimmaTech Biologics AGShigellosis

Start: 2025-02-17Target: 110Updated: 2026-01-27

Phase 3

Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)

CompletedNCT04204096

International Vaccine InstituteTyphoid

Start: 2020-02-04End: 2021-01-29Updated: 2021-08-27

To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)

CompletedNCT06177249

Hualan Biological Bacterin Co. Ltd.Rabies Human

Start: 2015-03-15End: 2016-05-01Updated: 2023-12-20

Phase 4

Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza

CompletedNCT01693380

Butantan InstituteAcute Respiratory Infection, Influenza

Start: 2009-05-31End: 2009-11-30Updated: 2023-04-04

An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell)

Sinovac Biotech Co., LtdHand, Foot and Mouth Disease

Start: 2022-07-30End: 2025-10-30Target: 474Updated: 2022-06-10

Related Papers

Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study

Human Vaccines & Immunotherapeutics2024-10-183 citations

A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.

2022-05-303 citations